These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17637682)

  • 1. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
    Delord JP; Bennouna J; Artru P; Perrier H; Husseini F; Desseigne F; François E; Faroux R; Smith D; Piedbois P; Naman H; Douillard JY; Bugat R
    Br J Cancer; 2007 Aug; 97(3):297-301. PubMed ID: 17637682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
    Bajetta E; Di Bartolomeo M; Buzzoni R; Mariani L; Zilembo N; Ferrario E; Lo Vullo S; Aitini E; Isa L; Barone C; Jacobelli S; Recaldin E; Pinotti G; Iop A
    Br J Cancer; 2007 Feb; 96(3):439-44. PubMed ID: 17245343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
    Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
    Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
    Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
    Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
    Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
    J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
    Bennouna J; Perrier H; Paillot B; Priou F; Jacob JH; Hebbar M; Bordenave S; Seitz JF; Cvitkovic F; Dorval E; Malek K; Tonelli D; Douillard JY
    Br J Cancer; 2006 Jan; 94(1):69-73. PubMed ID: 16404362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
    Méndez M; Alfonso PG; Pujol E; González E; Castañon C; Cerezuela P; López-Mateos Y; Cruz JJ
    Invest New Drugs; 2005 Jun; 23(3):243-51. PubMed ID: 15868381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
    Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
    Yamaguchi T; Matsumoto H; Yasutome M; Mori T; Takahashi K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):629-35. PubMed ID: 20495917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
    Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
    Kono T; Ebisawa Y; Tomita I; Chisato N; Kamiya K; Asama T; Ayabe T; Ashida T; Kohgo Y; Kasai S
    J Chemother; 2005 Apr; 17(2):224-7. PubMed ID: 15920910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
    Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
    Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.